METASTATIC CANCER

This phase 2 study tested two drugs—durvalumab and cetuximab—together in 35 people with head and neck cancer that had come back or spread and was no longer responding to standard treatments. The goal was to see if the combination could shrink tumors. The study is complete, and re…

This study tested whether a single, high dose of targeted radiation can control cancer that has spread to just a few spots (1-5 tumors). 150 adults with limited metastatic cancer received this treatment to see if it could delay further spread and improve survival. The goal is to …

This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with advanced colorectal cancer that had spread and stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. The study is comple…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment…

This early-phase study tested a new immune cell therapy called PD-L1 t-haNK in 16 adults with advanced solid cancers that had spread or could not be removed by surgery. The main goals were to check safety, find the best dose, and see if the treatment could shrink tumors. The ther…

This study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…

This early-phase trial tested a new oral drug called ART4215 in 93 people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose and check for side effects when given alone or with other cancer drugs (talazoparib or niraparib). …

This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This early-phase study tested a new treatment called NG-350A, a virus designed to target tumors and boost immune activity, combined with the immunotherapy drug pembrolizumab. Fourteen people with advanced epithelial cancers that had stopped responding to standard treatments recei…

This early-phase trial tested several combinations of cancer drugs, including niraparib, TSR-042, bevacizumab, and various chemotherapies, in 60 patients with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial has been completed, but…

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…

This phase 2 trial tested whether adding stereotactic body radiation therapy (SBRT) to standard checkpoint immunotherapy improves tumor response in 106 people with advanced metastatic cancer. Participants received either immunotherapy alone or immunotherapy plus SBRT to one tumor…

This study tested an experimental drug called ozuriftamab vedotin in 42 people with head and neck cancer that returned or spread. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received the drug alone or with other treatments, and …

This study tested a new radiation technique called SABR in 13 adults with cancer that had spread to more than 10 spots in the body. The goal was to see if giving high-dose, precise radiation to all cancer sites is safe. Researchers looked for side effects and quality of life chan…

This study tested a program called PRISM, which teaches skills like stress management and goal setting, to see if it helps racial minority patients with serious illnesses feel more resilient and communicate better with their healthcare providers. The study enrolled 28 seriously i…

This study looked at whether cancer patients already taking strong opioids like morphine can stop taking paracetamol without their pain getting worse. 204 adults with metastatic cancer and stable pain on both medications were randomly assigned to continue paracetamol or switch to…

This study tested whether psilocybin, a substance from certain mushrooms, given with therapy could safely reduce anxiety and depression in 55 people with metastatic cancer. Participants received counseling and a pharmaceutical-grade psilocybin dose. The trial focused on safety an…

This phase 1 trial tested whether a second psilocybin-assisted group therapy retreat is safe and helpful for anxiety in 15 patients with metastatic cancer who had only a partial response to their first retreat. Psilocybin, the active ingredient in magic mushrooms, is given in a g…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This study tested a new way for doctors to discuss CPR with older, seriously ill patients and their families. Instead of the usual conversation, doctors followed a step-by-step guide that focused on the patient's values and explained why CPR might not help. The goal was to see if…

This study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…

This study tested whether a planned meeting between a hospitalized cancer patient, their family doctor, and a specialist could reduce unplanned hospital visits. 667 adults with metastatic solid tumors were randomly assigned to either the standard discharge process or this organiz…

This study tested a program called ED GOAL that helps older adults with serious illnesses like heart failure or cancer discuss their end-of-life wishes with doctors and family, starting in the emergency department. Researchers enrolled 141 patients and measured whether the progra…

This study looked at whether a special planning tool, called a POST form, helps older adults (65+) get the medical care they prefer at the end of life. Researchers worked with 389 people, including those with dementia, to see if their treatment matched their wishes. The goal was …

This study tested whether giving cancer patients and their families a booklet of questions before a palliative care consultation helps them ask more questions or express more concerns. 121 adults with metastatic cancer and limited life expectancy took part. The booklet covered ei…

This completed study looked at 312 patients with advanced breast cancer who received either trastuzumab deruxtecan or sacituzumab govitecan. Researchers collected real-world information on side effects and how long the cancer was kept under control. The goal was to see how these …